Promising Diagnostic Approaches Emerging for Brain Pathologies: James Leverenz, MD
August 16th 2024The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic discussed new diagnostic techniques that show promise for advancing the understanding of brain pathologies like Alzheimer and Lewy Body diseases. [WATCH TIME: 3 minutes]
Stable MRI in Multiple Sclerosis Reveals Relapses as Acute Clinical Events
August 16th 2024Acute clinical events with stable MRI were more likely among patients with multiple sclerosis who had longer disease duration, received highly effective disease-modifying therapies, and were presented with fatigue.
Potential of Newer Techniques to Diagnose Dementia with Lewy Bodies: James Leverenz, MD
August 15th 2024The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic talked about challenges of accurately diagnosing dementia with Lewy bodies as well as new methods that show promise in guiding treatment. [WATCH TIME: 3 minutes]
Migraine Not Directly Linked to Traditional Cardiovascular Disease Risk Factors
August 14th 2024The study suggests that overall, migraine is not directly related to traditional CVRFs, and further research is needed, especially in younger populations, to explore these relationships over longer periods.
Early Clinical Development of Synapse-Focused Agent SPG302 for Alzheimer Disease
August 14th 2024Peter Vanderklish, PhD, chief science officer at Spingogenix, commented on a recently initiated phase 2 trial assessing investigational SPG302, a synaptic-regenerative agent in development for Alzheimer disease.
Challenges in Early Diagnosis of Frontotemporal Dementia in Clinical Settings: Chris Berka
August 13th 2024The CEO and cofounder at Advanced Brain Monitoring talked about how the early diagnosis of frontotemporal dementia is often mistaken for Alzheimer disease, but advancements in neuropsychological assessments and biomarker identification may improve accuracy. [WATCH TIME: 4 minutes]
Significance of Newly Approved IPX203 for Parkinson Disease
August 12th 2024In this opening segment, Hauser and Fernandez discussed the FDA approval of IPX203, a new long-acting levodopa formulation for Parkinson disease, highlighting its significance in improving treatment options and patient compliance.
Continued Evolution of Deep Brain Stimulation in Neurology: Jonathan Jagid, MD; Brian Noga, PhD
August 12th 2024A pair of neurologists from the University of Miami Miller School of Medicine provided insight on the various ways deep brain stimulation has changed and the potential treatment opportunities that lie ahead. [WATCH TIME: 4 minutes]
Tracking Neurodegenerative Disease Trajectories With EEG Biomarkers: Chris Berka
August 11th 2024The CEO and cofounder at Advanced Brain Monitoring discussed using EEG-based biomarkers to identify early markers that predict cognitive decline and aid in differential diagnosis for neurodegenerative diseases. [WATCH TIME: 4 minutes]
Higher Burden of Epilepsy Reported Among Sexual and Gender Minoritized Patient Groups
August 10th 2024Results from a survey study suggest the burden of epilepsy is high in sexual and gender minority patient populations, who already experience high risk of stigmatization, discrimination, and poor health outcomes.